SUMMIT研究:Optilume BPH导管系统治疗症状性良性前列腺增生的真实世界临床研究
SUMMIT研究是一项前瞻性、单臂、多中心、开放标签研究,在加拿大五个中心评估内镜下Optilume BPH药物涂层球囊(DCB)手术治疗良性前列腺增大所致下尿路症状(LUTS)的安全性与功能结局。12个月时IPSS从基线23.5±5.1降至10.8±7.5,QoL从4.7±1.3改善至2±1.6,Qmax从8.7±3.7 mL/s增至3个月时15.9±5.7 mL/s并在12个月维持14.7±6.9 mL/s,性功能评分无显著差异。结论认为该DCB手术在12个月内显示出显著的症状和功能改善。
要点
- Optilume BPH药物涂层球囊术后12个月IPSS和QoL显著改善。
- Qmax在3个月时明显提升,至12个月保持稳定。
- 性功能评分未见显著变化。
核心结论
- Optilume BPH药物涂层球囊手术在12个月内对症状性良性前列腺增生患者显示出显著的症状和功能改善。
研究设计与样本
- 前瞻性、单臂、多中心、开放标签研究,在加拿大五个中心开展,评估内镜下Optilume BPH(DCB)手术治疗良性前列腺增大所致LUTS的安全性。
- 研究时间为2022年7月至2025年8月,评估基线、3、6、12个月的功能结局。
主要发现
- IPSS从基线23.5±5.1降至12个月时10.8±7.5。
- QoL评分从基线4.7±1.3改善至12个月时2±1.6。
- Qmax从基线8.7±3.7 mL/s增至3个月时15.9±5.7 mL/s,12个月时维持14.7±6.9 mL/s。
- 性功能评分未见显著差异。
临床怎么用
- 对于症状性良性前列腺增生患者,Optilume BPH药物涂层球囊手术可作为改善LUTS和排尿功能的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To provides an overview of the functional and safety outcomes associated with the Optilume BPH catheter system. METHODS: This prospective, single-arm, multi-center, open-label study was conducted at five Canadian centers to evaluate the safety of the endoscopic Optilume BPH (DCB) procedure for LUTS due to benign prostate enlargement from July 2022 to August 2025. The study assessed functional outcomes at baseline, 3, 6, and 12 months. RESULTS: Thirty patients were included in this study, with a mean age of 63.1 ± 7.0 years. The mean prostate volume was 48.5 ± 16.6 mL. IPSS scores decreased from 23.5 ± 5.1 at baseline to 10.8 ± 7.5 at 12 months, while QoL scores improved from 4.7 ± 1.3 to 2 ± 1.6 over the same period. Qmax increased from 8.7 ± 3.7 mL/s to 15.9 ± 5.7 mL/s at 3 months, remaining stable at 14.7 ± 6.9 mL/s at 12 months. No significant differences were observed in sexual function scores. CONCLUSION: The Optilume BPH drug-coated balloon procedure demonstrated significant symptomatic and functional improvements over 12 months.
引用
- Siqueira MHB, Buksh O, Hammoud A, et al. The SUMMIT Study: A Real-world, Clinical Study to Evaluate the Performance of the Optilume BPH Catheter System in Men With Symptomatic Benign Prostatic Hyperplasia. Urology. 2026. PMID: 41985628. doi:10.1016/j.urology.2026.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。